Endostatin
- Generic Name
- Endostatin
- Drug Type
- Biotech
- CAS Number
- 187888-07-9
- Unique Ingredient Identifier
- 67RHC0R671
- Indication
Investigated for use/treatment in cancer/tumors (unspecified), macular degeneration, and diabetic retinopathy.
Local Injection and Systemic Therapy in the Treatment of NSCLC.
Phase 2
Not yet recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-09-30
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 84
- Registration Number
- NCT06618391
Intra-arterial Cisplatin Plus Rh-endostatin Combined With Systematic Chemotherapy in Osteosarcoma
Phase 1
Recruiting
- Conditions
- OsteosarcomaBone Cancer
- Interventions
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Shanghai 6th People's Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT06562673
- Locations
- 🇨🇳
Shanghai Jiao Tong University School of Medicine, Shanghai Sixth People's Hospital,, Shanghai, China
Recombinant Human Endostatin Combined With Envafolimab and Synchronal Radiochemotherapy
Phase 2
Not yet recruiting
- Conditions
- Locally Advanced Squamous Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-02-28
- Target Recruit Count
- 30
- Registration Number
- NCT06279754
A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer
Phase 2
Recruiting
- Conditions
- Advanced Solid TumorRefractory Tumor
- Interventions
- Radiation: RadiotherapyDrug: PD-1/PD-L1 inhibitorDrug: Granulocyte-macrophage colony-stimulating factor subcutaneous injectionDrug: Interleukin 2 subcutaneous injection
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Second Affiliated Hospital of Soochow University
- Target Recruit Count
- 30
- Registration Number
- NCT06047860
- Locations
- 🇨🇳
The Second Affiliated Hospital of SchoowUniversity, Suzhou, China
Envafolimab Combined With Endostar and Concurrent Chemoradiotherapy for Locally Advanced Primary Cervical Cancer
Not yet recruiting
- Conditions
- Cervical Cancer
- Interventions
- Drug: cis-platinumRadiation: radiation
- First Posted Date
- 2023-05-30
- Last Posted Date
- 2023-05-30
- Lead Sponsor
- Peking University Third Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05879796
Radiotherapy Combined With Endostatin and Capecitabine for NPC
- First Posted Date
- 2022-08-24
- Last Posted Date
- 2022-08-24
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 41
- Registration Number
- NCT05514275
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
🇨🇳People's Hospital of Quzhou, Quzhou, Zhejiang, China
🇨🇳the First Hospital of Jiaxing, Jiaxing, Zhejiang, China
Recombinant Human Angioendostatin /PD-1 Mab Combined With First-line Chemotherapy in the Treatment of Driver Gene Negative Advanced NSCLC
- First Posted Date
- 2022-07-07
- Last Posted Date
- 2022-07-07
- Lead Sponsor
- Affiliated Cancer Hospital & Institute of Guangzhou Medical University
- Target Recruit Count
- 38
- Registration Number
- NCT05448781
- Locations
- 🇨🇳
Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, Guangdong, China
Modified CV Regimen in Optic Pathway Glioma
Phase 2
Recruiting
- Conditions
- Optic GliomaPediatric Brain Tumor, Optic Nerve Glioma
- Interventions
- First Posted Date
- 2022-03-14
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Beijing Sanbo Brain Hospital
- Target Recruit Count
- 75
- Registration Number
- NCT05278715
- Locations
- 🇨🇳
Capital Medical University Sanbo Brain Hospital, Beijing, China
Efficacy and Safety of Recombinant Human Endostatin in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis
Phase 4
- Conditions
- Leptomeningeal Metastasis
- Interventions
- Drug: intrathcal methotrexateDrug: Targeted drugs for non-small cell lung cancer
- First Posted Date
- 2020-04-22
- Last Posted Date
- 2020-05-27
- Lead Sponsor
- Hui Bu
- Target Recruit Count
- 30
- Registration Number
- NCT04356118
Rh-endostatin Combined With Chemotherapy and Pembrolizumab for Advanced NSCLC
- First Posted Date
- 2019-09-19
- Last Posted Date
- 2020-02-07
- Lead Sponsor
- Guangzhou Institute of Respiratory Disease
- Target Recruit Count
- 186
- Registration Number
- NCT04094909
- Locations
- 🇨🇳
Zhou Chengzhi, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath